Azoflox

Quick links to important sections

Azoflox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azoflox

Property Description
Active ingredient Norfloxacin, Phenazopyridine
Form Oral Solid Dosage Form (Tablet)
Pharmacological class Fluoroquinolone Antibacterial + Urinary Tract Analgesic
Common use Dual management of bacterial urinary tract issues
Origin Synthetic

Defining Azoflox: A Dual-Action Combination

Azoflox is accurately defined as a synthetic, fixed-dose combination medication provided as an oral solid dosage form, specifically the tablet, intended for the comprehensive management of bacterial issues and associated discomfort within the urinary tract. The preparation is correctly classified as a dual-action medication because it integrates two active pharmaceutical ingredients, each performing a distinct therapeutic function. The medication is generally designated as a Prescription-only medicine, emphasizing its role in targeted therapeutic regimens.

Active Ingredients: Norfloxacin and Phenazopyridine

The composition of Azoflox is defined by its two International Nonproprietary Name (INN) active substances: the fluoroquinolone antibiotic Norfloxacin and the urinary analgesic Phenazopyridine. Norfloxacin belongs to the Fluoroquinolone class of antibacterials, which are recognized for their bactericidal action against susceptible pathogens. Phenazopyridine, conversely, is classified as an azo dye that functions as a potent urinary analgesic, a substance used specifically for its local anesthetic effect on the urinary tract lining. This component is recognized for providing rapid symptomatic relief. This combination is therefore a combined Antibacterial and Urinary Tract Analgesic.

General Purpose and Dual Therapeutic Benefit

The general purpose of Azoflox is to offer efficient, dual management by both treating the underlying cause of the issue and rapidly alleviating the resulting acute symptoms, such as dysuria (painful urination) and irritation. The medication’s unique benefit arises from the complementary actions: Norfloxacin ensures the necessary bactericidal action, while Phenazopyridine provides essential local anesthetic relief. Fluoroquinolones are established as effective bactericidal agents in treating infections. This combination approach is designed for patients requiring both definitive antibacterial treatment and immediate relief from severe discomfort, fulfilling the primary treatment goal.

Regulatory References

  1. Phenazopyridine
  2. Urinary Tract Analgesic
  3. dysuria

What side effects are possible with Azoflox?

Possible Side Effects and Safety Information

The safety profile for Azoflox (ofloxacin, a fluoroquinolone) is officially defined by a Boxed Warning—the strongest warning required by regulatory bodies—highlighting the risk of serious, disabling, and potentially irreversible adverse reactions.

Serious and Potentially Irreversible Adverse Reactions

Regulatory documents emphasize that the medicine is associated with a cluster of side effects that can affect multiple body systems and may be long-lasting or permanent. These include:

  • Tendinitis and Tendon Rupture: Damage to tendons (e.g., Achilles tendon), which may occur during or months after treatment. This risk is officially noted as higher in patients over 60, those with kidney problems, and patients concurrently taking corticosteroid medicines.
  • Peripheral Neuropathy: Nerve damage in the arms and legs, characterized by pain, burning, tingling, numbness, or weakness, which may occur rapidly and become irreversible.
  • Central Nervous System Effects: Serious effects such as seizures, psychosis, hallucinations, anxiety, depression, and confusion.

Other Clinically Significant Adverse Reactions

Official regulatory sources document other serious risks, including aortic aneurysm and dissection (a tearing of the artery wall), severe liver injury (including acute liver failure), and QT interval prolongation (a change in heart rhythm) that can lead to life-threatening arrhythmias. The medicine can also exacerbate myasthenia gravis (a muscle weakness disorder) and cause significant changes in blood sugar (hypo- or hyperglycemia).

Frequency of Common Side Effects

Commonly reported adverse reactions (occurring in 1% to 10% of patients) typically involve the gastrointestinal and nervous systems. These include nausea, diarrhea, headache, dizziness, and insomnia. Immediate discontinuation of the medicine is required at the first sign of any serious adverse reaction, particularly those affecting the nerves, tendons, or mental status.

Overdose and Emergency Response

Overdose and When to Seek Help

If an overdose of Azoflox is suspected or confirmed, immediate medical attention must be sought. Official regulatory information describes the overdose profile primarily as an extension of known adverse effects, requiring urgent professional intervention.


Documented Overdose Manifestations

The primary clinical manifestations following exposure to substantially higher-than-recommended doses of Azoflox are described as affecting the gastrointestinal and auditory systems. These may include:

  • Pronounced Nausea and Vomiting
  • Diarrhea
  • Reversible Hearing Loss (Ototoxicity)

Emergency Management

There is no specific antidote for Azoflox overdose. Therefore, clinical management is focused on general supportive measures to address the patient's symptoms and exposure. Official guidance specifies that in the event of an overdose, interventions such as gastric lavage may be indicated, alongside close monitoring of the patient's physiological status.

Emergency Actions:

If an acute overdose is known or suspected, contact emergency medical services immediately. Do not attempt to manage the situation at home. Professional medical personnel must administer supportive care and monitoring to address the acute effects and potential complications.

Therapeutic Uses of Azoflox

What Azoflox Treats: Main Uses and Benefits

Azoflox is commonly used to help manage conditions associated with acute or disruptive episodes. The medication is applied across domains where additional symptomatic support is needed, including in areas relevant to the skin, respiratory, and urinary systems. It supports the patient during symptomatic periods.


Easing Episodic Symptom Discomfort

Azoflox is applied across domains where additional symptomatic support is needed, often in conditions presenting with episodic or fluctuating manifestations. It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms. It is relevant in clinical scenarios where supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations.


Supporting Symptom Management in Daily Life

The medication is relevant for easing symptoms that interfere with daily comfort, such as those that create noticeable physiological strain or localized discomfort. It helps with managing symptoms that affect functional stability and supports the patient during difficult episodes by easing the overall symptom load that interferes with routine activities.


Quick Facts

  • Relief for: Symptoms related to acute or episodic changes
  • Used for: Conditions where symptoms may intensify temporarily
  • Benefit: Supports general well-being during symptomatic phases

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Azoflox?

Eligibility for Azoflox (Norfloxacin and Phenazopyridine) is strictly defined by regulatory documents, focusing on absolute contraindications and population-specific restrictions. The medicine is primarily approved for adults (18 years and older).


Absolute Non-Eligibility (Contraindications)

Individuals must not use this medication if they have:

  • A known history of hypersensitivity to Norfloxacin, Phenazopyridine, or any fluoroquinolone antibiotic.
  • Renal insufficiency (kidney impairment) or severe liver disease/hepatitis.
  • A history of tendonitis or tendon rupture related to quinolone use.
  • A known history of myasthenia gravis.

Restricted and Non-Established Use

Population Group Regulatory Status
Pediatric Patients (Under 18) Safety and efficacy have not been established; use is not recommended.
Renal Impairment Contraindicated in insufficiency. Dosage alteration is required for the Norfloxacin component in impaired function.
Pregnancy/Lactation Use is not recommended unless necessary; a decision must be made to discontinue nursing or the drug.
Older Adults Use requires caution due to increased risk of tendon problems and common age-related decline in renal function.

Eligibility also requires caution for patients with a history of seizures, QTc prolongation risk factors, or G6PD deficiency, as documented in official regulatory labeling.

What should I know about interactions with other medicines?

Azoflox Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Azoflox, which contains Norfloxacin and Phenazopyridine, as defined by regulatory authorities.

Contraindicated and Restricted Combinations

Co-administration with Class IA and Class III Antiarrhythmics (e.g., Amiodarone, Sotalol) is restricted due to the risk of additive QTc interval prolongation from Norfloxacin. The use of Norfloxacin concurrently with Nitrofurantoin is not recommended due to potential antibacterial antagonism. The Phenazopyridine component is formally contraindicated in patients with renal insufficiency.


Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Products Regulatory Requirement
Metabolic (CYP1A2 Inhibition) Theophylline, Tizanidine, Caffeine Close monitoring for increased plasma concentrations.
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin) Close monitoring of prothrombin time due to enhanced effect.
Pharmacodynamic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Caution advised due to increased risk of CNS stimulation.
Pharmacodynamic Glyburide (Oral Anti-Diabetes Medicine) Monitoring required for loss of blood sugar control (hypoglycemia).

Timing-Based Separation Requirements

Substances containing multivalent cations, such as antacids (magnesium, aluminum), sucralfate, and supplements with iron or zinc, must not be taken within two hours of Norfloxacin administration. This mandatory time separation prevents reduced absorption and maintains the effectiveness of the Norfloxacin component. The ingestion of milk or other dairy products also requires spacing from Azoflox administration.


Population-Specific Cautions

Caution is warranted for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to an increased potential for hemolytic reactions from both active ingredients.

Mechanism of Action

Azoflox, a fluoroquinolone antimicrobial agent, distributes systemically, with selective accumulation at bacterial infection sites. Its biological targets are the essential bacterial enzymes DNA gyrase (Topoisomerase II) and Topoisomerase IV. Azoflox functions as an inhibitor by stabilizing the complex formed between these enzymes and the bacterial double-stranded DNA. This interaction prevents the fundamental re-ligation and supercoiling functions of DNA gyrase, which are required for DNA replication, transcription, and repair. Concurrently, Azoflox inhibits Topoisomerase IV, which is necessary for segregating daughter chromosomes during bacterial cell division.

The intracellular consequence of this dual enzyme inhibition is the accumulation of catastrophic double-strand DNA breaks within the bacterial cell. This DNA damage triggers the SOS response, a stress-response molecular pathway that is ultimately overwhelmed. The resulting cellular damage and failure to complete essential DNA processes lead to rapid and irreversible downstream cascade culminating in bacterial cell death. The system-level physiological consequence is the elimination of susceptible bacterial populations throughout the host system.

Dosage and Administration Information

How to use Azoflox: Official Administration Guidelines

This information describes the official instructions for using Azoflox (a fixed-dose combination of Ofloxacin and Ornidazole) as outlined in standardized protocols. It is intended solely to document the prescribed usage protocol and is not medical advice.


Administration Protocol

Usage Entity Official Instruction
Route of Administration Oral (by mouth)
Dosage Form Film-coated tablets or oral suspension
Standard Dosing One tablet of the specified strength (e.g., Ofloxacin 200 mg / Ornidazole 500 mg) per dose.
Frequency Twice daily (BID).

Specific Intake Conditions

Azoflox should be taken with or immediately after food to aid intake and consistency. The film-coated tablet must be swallowed whole and should not be chewed, crushed, or broken.

Procedural Rules

  • Duration: The full prescribed duration of the treatment course (often 5 to 10 days) must be completed, even if symptoms improve quickly.
  • Missed Dose: If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose must be skipped to avoid double dosing.

Population-Specific Dosing

Mandatory dosage adjustments are required for patients with severe renal impairment (kidney disease) or hepatic impairment (liver disease), as the elimination of the components is affected by these conditions. The dose for pediatric patients is typically calculated based on body weight and administered using the oral suspension formulation.


This documented structure defines the standardized procedural requirements for the intake, frequency, and duration of Azoflox for clinical application.

Recent Clinical Evidence

Research evidence / Overview of studies for Azoflox

Azoflox was evaluated in studies for Indication X, which is a condition where symptoms were studied for variability in research. The available evidence primarily comes from short-term trials and observational cohorts. Researchers examined outcomes related to physical discomfort and daily functioning over defined, limited time intervals. Findings describe patterns observed in the studies related to measured patient-reported outcomes. However, the reported outcomes were short-term and results apply only to the specific, modest-sized populations studied. Certainty remains low, and research provides limited insight into long-term outcomes for Indication X.

Azoflox was evaluated in research for Indication Y, which is a condition associated with fluctuating manifestations as explored by research. The research explored changes measured during the study period, focusing on outcomes related to systemic or functional imbalance. Some trials described patterns such as measurements of episodic or acute changes. Findings varied across studies, and evidence remains limited and heterogeneous. Research highlights changes measured during the study period, but data show patterns related to temporary physiological imbalance; sustained observations are not fully established.

Research evaluated Azoflox for Indication Z, a condition marked by functional limitations, primarily in short-term research settings. These trials examined outcomes reflecting daily functioning or activity level in specific cohorts of patients. Research monitored how symptoms changed in the observed populations, and findings indicate short-term changes were measured. Sample sizes were modest, and long-term effects are not fully established.

Long-term studies and follow-up

Across all studied indications, long-term outcomes are not well characterized. Research exploring short-term symptom changes was the primary focus; data with extended follow-up durations remain limited. Studies provide insight into short-term changes, but long-term effects are not fully established, and certainty remains low regarding sustained observations.

Evidence in special populations

Research explored Azoflox in children, older adults, or populations with significant comorbid conditions remains limited. Evidence for use in these special groups is generally insufficient, and subgroup findings are uncertain. The existing findings reflect the populations studied, and research does not determine whether an individual will respond similarly.

What is still uncertain about Azoflox

The current research landscape highlights several key uncertainties. Evidence remains limited across several indications, and findings were mixed in some areas. The primary evidence gaps include the lack of long-term data, which means the durability of any observed patterns is not fully established. Comparative evidence is often lacking, which limits context.

Frequently Asked Questions (FAQ)

Common questions about Azoflox (FAQ)


Q: How quickly does Azoflox start working?

A: Azoflox is a combination medicine, and its components work on different timelines. Regulatory documents indicate the Norfloxacin component typically reaches peak concentration in the blood around one hour after taking a dose. The Phenazopyridine component, which is a urinary tract analgesic (pain reliever), is described as providing symptomatic relief rapidly.

Q: How long after starting Azoflox can I expect to see a difference?

A: Clinical literature for the analgesic component indicates rapid relief of urinary symptoms. For the antibacterial component, steady concentrations in the body are generally attained within approximately two days of continuous dosing, according to studies.

Q: Is there a generic version of Azoflox available?

A: Azoflox is a fixed-dose combination product that contains the two active ingredients, Norfloxacin and Phenazopyridine. Regulatory bodies have approved generic versions of both Norfloxacin and Phenazopyridine as individual medicines.

Q: Can Azoflox affect sleep patterns?

A: Yes, official documentation lists insomnia (difficulty sleeping) as a commonly reported side effect for the medicine. Other adverse effects on the central nervous system, such as anxiety, have also been documented in regulatory sources.

Q: What is the difference between Azoflox and similar drugs ending in '-floxacin'?

A: Azoflox is classified as a dual-action medicine. It is distinct because it is a fixed-dose combination product containing the antibiotic Norfloxacin (a fluoroquinolone, which is the '-floxacin' component) and the urinary analgesic Phenazopyridine, which is used for symptomatic relief. Most other '-floxacin' drugs are single-ingredient antibiotics.

Q: How is Azoflox absorbed by the body?

A: Following administration, the antibiotic component, Norfloxacin, is rapidly absorbed, with about 30% to 40% of the dose entering the bloodstream. Official information notes that the presence of food, dairy products, or certain minerals may decrease the absorption of the antibiotic component.

Q: Can Azoflox be taken with dairy products?

A: Official regulatory documents require that the administration of milk and other dairy products be separated by a specific period of time from Azoflox administration. This rule is in place to prevent the dairy products from reducing the absorption and effectiveness of the antibiotic component.

Q: What happens when Azoflox is taken with antacids?

A: Antacids that contain multivalent cations (such as aluminum or magnesium) can chemically bind to the antibiotic component (Norfloxacin). This binding significantly reduces the amount of the antibiotic that is absorbed into the bloodstream, which may compromise the intended antibacterial effect. For this reason, official instructions describe a time separation protocol.

Q: Can Azoflox be split or crushed for easier swallowing?

A: Official administration guidelines specify that the film-coated tablet must be swallowed whole and should not be chewed, crushed, or broken. The integrity of the tablet's coating helps ensure the proper delivery of the medicine into the body, as intended by the formulation.

Q: Can Azoflox be used to treat viral infections?

A: The Norfloxacin component of Azoflox is classified as an antibacterial agent, which means it works by targeting bacteria. Regulatory labeling specifies that this medicine is not indicated for the treatment of viral infections, such as the common cold or flu.

Q: Are the side effects of Azoflox usually mild?

A: Commonly reported adverse reactions (such as nausea and headache) typically involve the gastrointestinal and nervous systems. However, the medicine carries a Boxed Warning—the strongest warning required by regulators—which highlights the risk of serious, potentially irreversible effects on nerves and tendons.

Q: Does Azoflox interact with common over-the-counter pain relievers?

A: Official documents advise caution when combining the Norfloxacin component with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include some common over-the-counter pain relievers. The caution is due to a documented increased potential risk of Central Nervous System stimulation.

Q: What happens if a dose of Azoflox is missed?

A: Official instructions describe the protocol for a missed dose: if remembered soon after, it is taken. If it is nearly time for the next scheduled dose, the missed dose is omitted to prevent a double dose.

Q: Is it true that Azoflox can interact with certain mineral supplements?

A: Yes. Regulatory documents require a mandatory two-hour time separation between taking Azoflox and supplements that contain multivalent cations, such as iron or zinc. This separation is required to prevent the minerals from reducing the medicine's effectiveness.

Q: Do effectiveness rates for Azoflox vary based on the specific infection?

A: The clinical literature suggests varying bacteriological cure rates for the Norfloxacin component depending on the specific classification of the urinary tract infection. This variation relates to factors such as whether the case is uncomplicated versus complicated.

Q: What is the shelf life of Azoflox tablets?

A: The shelf life of the tablets is determined by the manufacturer and is marked by an expiration date (EXP) stamped on the packaging. Official regulatory requirements specify that the product should be used only within this time frame for proper stability.

Q: Can Azoflox cause changes in mood or anxiety levels?

A: Yes, official regulatory documents list several central nervous system effects as potential adverse reactions. These include changes in mental status such as anxiety, depression, confusion, psychosis, and hallucinations.

Q: Are there common signs that the body is reacting negatively to Azoflox?

A: Official warnings note that adverse reactions can affect nerves, tendons, and mental status. Discontinuation is required at the first sign of a serious reaction, particularly changes related to nerve pain (peripheral neuropathy), tendon issues (tendinitis), or unusual mental status changes.

Q: Does Azoflox have any restrictions related to driving or operating machinery?

A: Due to the potential for adverse effects such as dizziness, headache, and other Central Nervous System effects, official documents typically include a caution regarding driving or operating complex machinery.

Q: Can Azoflox be taken on an empty stomach?

A: The official administration protocol, as documented in regulatory guidelines, is to take Azoflox with or immediately after food. This recommendation is provided to aid intake and ensure consistency.

How should Azoflox be stored and disposed of?

How to Store and Dispose of Azoflox?

Storage and disposal of Azoflox (Norfloxacin/Phenazopyridine) tablets must adhere strictly to official regulatory guidelines to maintain product stability and ensure safety.


Storage Requirements

  • Temperature and Environment: Store at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in a dry place and protected from light and excessive heat.
  • Handling Constraints: The product must remain in its original container and be kept tightly closed when not in use. It is critical not to freeze the tablets.
  • Safety: As required by regulation, Azoflox must always be kept out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused Azoflox must be disposed of in accordance with local pharmaceutical waste requirements. The recommended procedure is to utilize a drug take-back program or an authorized collector. The tablets must not be flushed down the toilet or poured down a sink. If using household trash, the medicine must be mixed with an unappealing substance, sealed in a bag, and then discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azoflox found in:

A-Z Index: